1-10 of 10
Kevin Philip
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML

Warren Fiskus, Christopher P Mill, Prithviraj Bose, Lucia Masarova, Naveen Pemmaraju, Andrew Dunbar, Christine Birdwell, John A Davis, Kaberi Das, Hanxi Hou, Taghi Manshouri, Antrix Jain, Anna Malovannaya, Kevin Philip, Noor Alhamadani, Alicia Matthews, Katie Lin, Lauren Flores, Sanam Loghavi, Courtney D. DiNardo, Xiaoping Su, Raajit K. Rampal, Kapil N Bhalla
Journal: Blood
Blood blood.2024026388.
https://doi.org/10.1182/blood.2024026388
Published: 2024
Includes: Supplemental data
Journal Articles

Evaluation of the Lethal Activity and Its Mechanism of Tasquinimod in Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Warren C. Fiskus, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John A. Davis, Hanxi Hou, Kevin Philip, Alicia Matthews, Taghi Manshouri, Surbhi Sharma, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, Kapil N. Bhalla
Journal: Blood
Blood (2024) 144 (Supplement 1): 3142.
https://doi.org/10.1182/blood-2024-203947
Published: 2024
Journal Articles

Pre-Clinical Efficacy of CDK7 Inhibitor-Based Combinations in Cellular Models of Advanced Myeloproliferative Neoplasms (MPN) Transformed to AML

Warren C. Fiskus, Prithviraj Bose, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, John Davis, Kaberi Das, Hanxi Hou, Taghi Manshouri, Kevin Philip, Noor Alhamadani, Alicia Matthews, Sanam Loghavi, Kapil N. Bhalla
Journal: Blood
Blood (2023) 142 (Supplement 1): 1783.
https://doi.org/10.1182/blood-2023-185089
Published: 2023
Journal Articles

Notable Efficacy of Co-Treatment with FHD-286, a Dual BRG1/BRM ATP-Ase Inhibitor, and Menin or BET Inhibitor, Decitabine or Venetoclax Against AML with MLL-r or Mutant NPM1

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Branko Cuglievan, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2023) 142 (Supplement 1): 4160.
https://doi.org/10.1182/blood-2023-182575
Published: 2023
Journal Articles

Preclinical Studies Demonstrating Efficacy of Tasquinimod in Models of Advanced Myeloproliferative Neoplasm (MPN) in Blastic Phase

Warren C. Fiskus, Lucia Masarova, Christopher Peter Mill, Christine Birdwell, Kaberi Das, John Davis, Hanxi Hou, Noor Alhamadani, Kevin Philip, Alicia Matthews, Taghi Manshouri, Tapan M. Kadia, Courtney D. DiNardo, Prithviraj Bose, Naveen Pemmaraju, Sanam Loghavi, Marie Törngren, Kapil N. Bhalla
Journal: Blood
Blood (2023) 142 (Supplement 1): 741.
https://doi.org/10.1182/blood-2023-185031
Published: 2023
Journal Articles

Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background

Warren C. Fiskus, Jessica Piel, Murphy Hentemann, Christopher Peter Mill, Christine E Birdwell, Kaberi Das, John A. Davis, Noor Alhamadani, Kevin Philip, Tapan M. Kadia, Naval Daver, Sanam Loghavi, Courtney D. DiNardo, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 8819–8820.
https://doi.org/10.1182/blood-2022-164513
Published: 2022
Journal Articles

Bruton's Tyrosine Kinase (BTK) Degrader Nx-2127 Exhibits Lethal Activity and Synergy with Venetoclax and BET Protein Inhibitor Against MCL Cells Sensitive or Resistant to Covalent BTK Inhibitors

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Noor Alhamadani, Kevin Philip, May Tan, Robert A Brown, Michael R Green, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 5980–5981.
https://doi.org/10.1182/blood-2022-168483
Published: 2022
Journal Articles

Efficacy of Vcp/p97 Inhibitor, CB-5339, Alone and in Combinations Against High-Risk AML, Including Those with Genetic Lesion in TP53

Warren C. Fiskus, Kaberi Das, Christopher Peter Mill, Christine E Birdwell, John A. Davis, Kevin Philip, Noor Alhamadani, Tapan M. Kadia, Naval Daver, Koji Sasaki, Koichi Takahashi, Sanam Loghavi, Courtney D. DiNardo, Jesse Vargas, Kapil N. Bhalla
Journal: Blood
Blood (2022) 140 (Supplement 1): 8807–8808.
https://doi.org/10.1182/blood-2022-165012
Published: 2022
Journal Articles

Clinical-Stage Menin Inhibitor KO-539 Is Synergistically Active with Multiple Classes of Targeted Agents in KMT2A-r and NPM1-Mutant AML Models

John A. Davis, Warren C. Fiskus, Naval Daver, Christopher Peter Mill, Christine Birdwell, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Mollie Leoni, Francis Burrows, Kapil N. Bhalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 3357.
https://doi.org/10.1182/blood-2021-149831
Published: 2021
Journal Articles

Preclinically Effective Menin Inhibitor SNDX-50469 and SNDX-5613-Based Combinations Against MLL1-Rearranged (MLL-r) or NPM1-Mutant AML Models

Warren C. Fiskus, Christopher Peter Mill, Christine Birdwell, John A. Davis, Arnold Salazar, Kevin Philip, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Gerard M. McGeehan, Naval Daver, Kapil N. Bhalla
Journal: Blood
Blood (2021) 138 (Supplement 1): 3340.
https://doi.org/10.1182/blood-2021-152060
Published: 2021